Oragenics, Inc.OGENNYSE
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank90
3Y CAGR+145.6%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+145.6%/yr
vs -48.1%/yr prior
Acceleration
+193.7pp
Accelerating
Percentile
P90
Near historical high
vs 3Y Ago
14.8x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 107.01% |
| Q2 2025 | 31.66% |
| Q1 2025 | -79.49% |
| Q4 2024 | 89.43% |
| Q3 2024 | -3.06% |
| Q2 2024 | 36.68% |
| Q1 2024 | -93.99% |
| Q4 2023 | 1335.24% |
| Q3 2023 | -61.66% |
| Q2 2023 | 19.98% |
| Q1 2023 | 419.71% |
| Q4 2022 | -118.84% |
| Q3 2022 | 7.22% |
| Q2 2022 | -21.36% |
| Q1 2022 | 151.36% |
| Q4 2021 | -63.06% |
| Q3 2021 | 43.76% |
| Q2 2021 | -24.33% |
| Q1 2021 | -2.73% |
| Q4 2020 | -4.17% |
| Q3 2020 | -69.70% |
| Q2 2020 | 210.93% |
| Q1 2020 | 34.53% |
| Q4 2019 | -10.03% |
| Q3 2019 | -20.92% |
| Q2 2019 | 60.71% |
| Q1 2019 | 34.58% |
| Q4 2018 | 13.48% |
| Q3 2018 | 24.30% |
| Q2 2018 | -4.12% |
| Q1 2018 | 62.67% |
| Q4 2017 | -18.18% |
| Q3 2017 | 64.60% |
| Q2 2017 | -46.06% |
| Q1 2017 | -36.79% |
| Q4 2016 | 92.03% |
| Q3 2016 | 13.81% |
| Q2 2016 | -34.54% |
| Q1 2016 | -7.61% |
| Q4 2015 | 14.77% |